/TNXP
TNXP Stock - Tonix Pharmaceuticals Holding Corp.
Healthcare|BiotechnologyNASDAQ
$17.09-6.15%
$1.12 (-6.15%) • Dec 19
46
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.10
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.47
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $18.80
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TNXP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.92 – $17.26
TARGET (TP)$19.65
STOP LOSS$15.72
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.83
52W High$69.97
52W Low$6.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.09M | $7.77M | N/A | N/A | N/A |
| Gross Profit | $2.33M | $3.03M | N/A | N/A | $-27,000 |
| Gross Margin | 23.1% | 39.0% | N/A | N/A | N/A |
| Operating Income | $-136,701,000 | $-118,380,000 | $-112,091,000 | $-92,312,000 | $-50,511,000 |
| Net Income | $-130,036,000 | $-116,658,000 | $-110,218,000 | $-92,287,000 | $-50,463,000 |
| Net Margin | -1288.3% | -1501.8% | N/A | N/A | N/A |
| EPS | $-176.60 | $-6368.84 | $-811.68 | $-163968.00 | $-5056.00 |
Company Overview
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 18th 2022 | Noble Capital Markets | Initiation | Outperform | - |
Earnings History & Surprises
TNXPBeat Rate
50%
Last 18 quarters
Avg Surprise
+1.6%
EPS vs Estimate
Beats / Misses
9/5
4 met exactly
Latest EPS
$-3.59
Q4 2025
EPS Surprise History
Q1 24
+47.6%
$-0.86vs$-1.64
Q2 24
+44.9%
$-2747.60vs$-4984.03
Q3 24
-94.6%
$-1928.00vs$-991.00
Q4 24
+88.7%
$-23.00vs$-203.00
Q1 25
-56.8%
$-9.77vs$-6.23
Q2 25
+12.1%
$-2.84vs$-3.23
Q3 25
-24.5%
$-3.86vs$-3.10
Q4 25
0.0%
$-3.59vs$-3.59
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $-3.16 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-3.59 | $-3.59 | 0.0% | = MET |
Q3 2025 | Aug 11, 2025 | $-3.10 | $-3.86 | -24.5% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-3.23 | $-2.84 | +12.1% | ✓ BEAT |
Q1 2025 | Mar 18, 2025 | $-6.23 | $-9.77 | -56.8% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-203.00 | $-23.00 | +88.7% | ✓ BEAT |
Q3 2024 | Aug 16, 2024 | $-991.00 | $-1928.00 | -94.6% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-4984.03 | $-2747.60 | +44.9% | ✓ BEAT |
Q1 2024 | Mar 25, 2024 | $-1.64 | $-0.86 | +47.6% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-4760.38 | $-5846.65 | -22.8% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-8881.79 | $-8562.30 | +3.6% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-7987.22 | $-10383.39 | -30.0% | ✗ MISS |
Q1 2023 | Mar 13, 2023 | $-12579.87 | $-11182.11 | +11.1% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-14377.00 | $-13777.96 | +4.2% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-29153.36 | $-24361.02 | +16.4% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-31897.85 | $-31897.85 | 0.0% | = MET |
Q1 2022 | Mar 14, 2022 | $-44656.98 | $-44656.98 | 0.0% | = MET |
Q4 2021 | Nov 8, 2021 | $-44656.98 | $-31897.85 | +28.6% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-44656.98 | $-44656.98 | 0.0% | = MET |
Latest News
Tonix Pharma Announces Licensing Exclusive Worldwide Rights To TNX-4900, Small-Molecule S1R Antagonist With Demonstrated Analgesic Activity In Multiple Models Of Neuropathic Pain
📈 PositiveBenzinga•Dec 16, 2025, 12:07 PM
Tonix Pharma Announces FDA Clears IND Application To Support Clinical Development Of TNX-102 SL 5.6 Mg For Treatment Of Major Depressive Disorder In Adults
📈 PositiveBenzinga•Nov 24, 2025, 12:13 PM
Tonix Pharmaceuticals Amends Sales Agreement With Alliance Global Partners; Increases Offering Price To $400M
➖ NeutralBenzinga•Nov 21, 2025, 09:54 PM
Tonix Pharmaceutical Increases Share Repurchase Program To $35M
📈 PositiveBenzinga•Nov 18, 2025, 10:29 PM
Tonix Pharmaceuticals Holding shares are trading higher after the company announced commercial availability of TONMYA.
📈 PositiveBenzinga•Nov 17, 2025, 01:58 PM
Tonix Pharmaceuticals' TONMYATM Now Commercially Available Across U.S.
📈 PositiveBenzinga•Nov 17, 2025, 12:10 PM
Tonix Pharmaceuticals Q3 EPS $(3.59) Misses $(3.58) Estimate, Sales $3.290M Beat $3.100M Estimate
➖ NeutralBenzinga•Nov 10, 2025, 09:34 PM
Tonix Teams Up With Mass General To Test New Antibody For Kidney Transplant Patients
📈 PositiveBenzinga•Nov 4, 2025, 12:15 PM
Tonix Pharmaceuticals To Highlight Advancements In CNS, Immunology, And Infectious Disease Programs At BIO-Europe 2025
📈 PositiveBenzinga•Oct 28, 2025, 11:09 AM
Tonix Pharma Presents Data On Tonmya, Which Was Investigated As TNX-102 SL, At 2025 ACR Convergence
➖ NeutralBenzinga•Oct 27, 2025, 11:02 AM
Tonix Starts First Patient Dosing in Study Testing Oxytocin Therapy for Rare Disorder
📈 PositiveBenzinga•Oct 22, 2025, 11:11 AM
Tonix Pharma To Present Tonmya (TNX-102 SL) Poster At ACR Convergence 2025
➖ NeutralBenzinga•Oct 21, 2025, 11:10 AM
Tonix Pharmaceuticals Presents Preclinical TNX-801 Mpox Vaccine Data At World Vaccine Congress–Europe 2025, Showing Durable Single-Dose Protection And Strong Immunogenicity
📈 PositiveBenzinga•Oct 17, 2025, 11:04 AM
Tonix Pharmaceuticals CEO Highlights TNX-1500 Progress and Anti-CD154 Therapy in Organ Transplantation at Japan Conference
📈 PositiveBenzinga•Oct 14, 2025, 11:13 AM
Tonix Pharmaceuticals To Present Single-Dose TNX-801 Mpox Vaccine And Join Panel At World Vaccine Congress Europe 2025 In Amsterdam On Oct 14–16
📈 PositiveBenzinga•Oct 9, 2025, 11:15 AM
Tonix Pharma Plans To Progress TNX-2900 Program For Treatment Of PWS Into Phase 2 Clinical Trial
📈 PositiveBenzinga•Sep 29, 2025, 11:08 AM
Tonix Pharmaceuticals Completes Type B Pre-IND Meeting With FDA For TNX-102 SL For Treatment Of Major Depressive Disorder
➖ NeutralBenzinga•Sep 18, 2025, 12:03 PM
Tonix Pharmaceuticals Announces In-Licensing Of TNX-4800 Monoclonal Antibody For Annual Lyme Disease Prevention Across US Endemic Regions
📈 PositiveBenzinga•Sep 17, 2025, 11:09 AM
Tonix Presents Clinical Data On Tonmya For Treatment Of Fibromyalgia At PAINWEEK Conference 2025; Phase 3 Data Support Q4 Launch Following PAINWEEK Showcase
📈 PositiveBenzinga•Sep 8, 2025, 11:04 AM
Tonix drops 20% despite winning approval for fibromyalgia drug
📉 NegativeSeeking Alpha•Aug 18, 2025, 03:49 PM
Frequently Asked Questions about TNXP
What is TNXP's current stock price?
Tonix Pharmaceuticals Holding Corp. (TNXP) is currently trading at $17.09 per share. The stock has moved -6.15% today.
What is the analyst price target for TNXP?
No analyst price targets are currently available for this stock.
What sector is Tonix Pharmaceuticals Holding Corp. in?
Tonix Pharmaceuticals Holding Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TNXP's market cap?
Tonix Pharmaceuticals Holding Corp. has a market capitalization of $0.15 billion, making it a small-cap company.
Does TNXP pay dividends?
No, Tonix Pharmaceuticals Holding Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPLT
Applied Therapeutics, Inc.
$0.13
Mkt Cap: $0.0B
AVTX
Avalo Therapeutics, Inc.
$18.60
Mkt Cap: $0.2B
ELDN
Eledon Pharmaceuticals, Inc.
$1.64
Mkt Cap: $0.1B
ELTX
Elicio Therapeutics, Inc.
$7.94
Mkt Cap: $0.1B
FATE
Fate Therapeutics, Inc.
$1.05
Mkt Cap: $0.1B
FBRX
Forte Biosciences, Inc.
$29.69
Mkt Cap: $0.4B
IPHA
Innate Pharma S.A.
$1.75
Mkt Cap: $0.1B
MCRB
Seres Therapeutics, Inc.
$14.98
Mkt Cap: $0.1B
MIST
Milestone Pharmaceuticals Inc.
$2.15
Mkt Cap: $0.2B
NKTX
Nkarta, Inc.
$1.79
Mkt Cap: $0.1B
Explore stocks similar to TNXP for comparison